A Phase 4 interventional study of Placebo and Rifaximin in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Terminated at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 16th largest by enrollment, is one of 4 that started in 2013, is one of 8 in phase 4, and was the 10th registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Belgium, Netherlands
Ages 18–80
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2013.
This study's enrollment of 6 is below the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 94 across the 18 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 7 studies filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rifaximin, oral, 550 mg BID, 6 months of treatment
Drug: Rifaximin
Placebo, oral, 0 mg BID, 6 months of treatment
Drug: Placebo
Placebo, oral, 0 mg BID, 6 months of treatment
Rifaximin, oral, 550 mg BID, 6 months treatment
Also known as: XIFAXAN® Tablets
Proportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode
Time frame: 6 Months
Proportion of Participants With HE-related Hospitalization
Time frame: 6 Months
| Milestone | Rifaximin | Placebo |
|---|---|---|
| Started | 3 | 3 |
| Completed | 0 | 1 |
| Not completed | 3 | 2 |
| Withdrew: Hepatic encephalopathy breakthrough | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 2 |
| Participants | Rifaximin | Placebo |
|---|---|---|
| Proportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode | 1 | 1 |
| Participants | Rifaximin | Placebo |
|---|---|---|
| Proportion of Participants With HE-related Hospitalization | 1 | 1 |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin | 2/3 (66.7%) | 3/3 (100%) | 2/3 (66.7%) |
| Placebo | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Rifaximin | Placebo |
|---|---|---|
| Hepatic cirrhosisHepatobiliary disorders | 2/3 | 0/3 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 |
| Renal failure acuteRenal and urinary disorders | 1/3 | 0/3 |
| Septic shockInfections and infestations | 1/3 | 0/3 |
| SepsisInfections and infestations | 1/3 | 0/3 |
| AscitesGastrointestinal disorders | 1/3 | 1/3 |
| BronchitisInfections and infestations | 1/3 | 0/3 |
| Hepatic encephalopathyNervous system disorders | 1/3 | 1/3 |
| Hepatorenal syndromeHepatobiliary disorders | 1/3 | 0/3 |
| Event | Rifaximin | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 1/3 | 0/3 |
| Ammonia increasedInvestigations | 1/3 | 0/3 |
| AnemiaBlood and lymphatic system disorders | 1/3 | 0/3 |
| AnosmiaNervous system disorders | 0/3 | 1/3 |
| Disturbance in attentionNervous system disorders | 0/3 | 1/3 |
| DysesthesiaNervous system disorders | 0/3 | 1/3 |
| DysgeusiaNervous system disorders | 0/3 | 1/3 |
| DyslipidemiaMetabolism and nutrition disorders | 1/3 | 0/3 |
| Escherichia infectionInfections and infestations | 0/3 | 1/3 |
| FatigueGeneral disorders | 1/3 | 0/3 |
| Age, Categorical(Participants) | Rifaximin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 2 | 5 |
| >=65 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Rifaximin | Placebo | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Rifaximin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 0 | 3 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Apr 2013 to primary completion in Feb 2016, 34 months.
Results were first posted in Jan 2024, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →